Molecular diagnostics developer Good Start Genetics Inc. last week presented positive data on its next generation sequencing technology. According to the Cambridge, Mass., company the data, from 16,500 patients presented at the American Society for Reproductive Medicine (ASRM) annual meeting on its GoodStart Select carrier screening test, showed that 8.4 percent of carriers or genetic diseases such as cystic fibrosis would have been missed using other technologies available in the market today.
Help employers find you! Check out all the jobs and post your resume.
